… advances, lung cancer remains the leading cause of cancer-… of treating advanced non–small-cell
lung cancer (NSCLC). Recent … a negative effect of AS therapy on erlotinib effectiveness. …

… of EGFR signaling in lung cancer, the beneficial effects of erlotinib (an EGFR inhibitor) on …
in human lung cancers, we conducted a phase I trial of combined erlotinib and dasatinib in …

… erlotinib is much less effective in non–small-cell lung cancer (… may alternatively promote
cell survival or type II cell death. … evaluated the effect of the autophagy inhibitor on erlotinib-…

… functional interaction between the EGFR and PKC pathways in lung cancer and provides
a clinically exploitable strategy for erlotinib-less sensitive non-small cell lung cancer patients. …

… In contrast, in EGFR-negative patients, there was no apparent erlotinib survival effect with
median survival on erlotinib 5.2 months and placebo 7.5 months (HR, 1.01; 95% CI, 0.7-1.6, P …

… affects the modulation of AKT–survivin signaling by erlotinib, we examined the effects of
erlotinib on … in these cell lines by immunoblot analysis. Similar to our observations with H1650 …

… To further understand the role of p27 KIP1 in G 1 /S arrest and cell growth inhibition by
erlotinib, we determined its effect on the expression of p27 KIP1 at transcriptional and …

… Lung cancer is the leading cause of cancer death worldwide and is commonly classified into
small and non-small cell lung cancer (… major types: (1) squamous cell carcinomas (SCC), (2) …

… Chemotherapy was associated with more grade 3 or 4 toxic effects than was erlotinib (… either
event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased …

… in Unresectable NSCLC (SATURN; BO18192) study to investigate the effect of erlotinib
as maintenance therapy on PFS in patients with non-progressive disease following first-line …